Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
Identifieur interne : 000244 ( PubMed/Curation ); précédent : 000243; suivant : 000245Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
Auteurs : Antonios Kolocouris [Grèce] ; Philip Spearpoint ; Stephen R. Martin ; Alan J. Hay ; Marta L Pez-Querol ; Francesc X. Sureda ; Elizaveta Padalko ; Johan Neyts ; Erik De ClercqSource :
- Bioorganic & medicinal chemistry letters [ 1464-3405 ] ; 2008.
Descripteurs français
- KwdFr :
- Adamantane (), Adamantane (analogues et dérivés), Adamantane (pharmacologie), Adamantane (synthèse chimique), Amantadine (pharmacologie), Antiviraux (), Antiviraux (pharmacologie), N-Méthyl-aspartate (antagonistes et inhibiteurs), Protéines de la matrice virale (), Relation structure-activité, Structure moléculaire, Virus de la grippe A ().
- MESH :
- analogues et dérivés : Adamantane.
- antagonistes et inhibiteurs : N-Méthyl-aspartate.
- pharmacologie : Adamantane, Amantadine, Antiviraux.
- synthèse chimique : Adamantane.
- Adamantane, Antiviraux, Protéines de la matrice virale, Relation structure-activité, Structure moléculaire, Virus de la grippe A.
English descriptors
- KwdEn :
- Adamantane (analogs & derivatives), Adamantane (chemical synthesis), Adamantane (chemistry), Adamantane (pharmacology), Amantadine (pharmacology), Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Influenza A virus (drug effects), Molecular Structure, N-Methylaspartate (antagonists & inhibitors), Structure-Activity Relationship, Viral Matrix Proteins (drug effects).
- MESH :
- chemical , analogs & derivatives : Adamantane.
- chemical , antagonists & inhibitors : N-Methylaspartate.
- chemical , chemical synthesis : Adamantane.
- chemical , chemistry : Adamantane, Antiviral Agents.
- chemical , drug effects : Viral Matrix Proteins.
- chemical , pharmacology : Adamantane, Amantadine, Antiviral Agents.
- drug effects : Influenza A virus.
- Molecular Structure, Structure-Activity Relationship.
Abstract
The new 2-alkyl-2-aminoadamantanes and analogues 4-10 were designed and synthesized by simplification of the structure of the potent anti-influenza virus A spiranic aminoadamantane heterocycles 2 and 3. The aim of the present work was to examine the effects of bulky and extended lipophilic moieties attached to amantadine 1 on binding to the M2 channel and the resulting antiviral potency. The binding affinities of the compounds to the M2 protein of influenza virus A/chicken/Germany/27 (Weybridge strain; H7N7) were measured for the first time using an assay based on quenching of Trp-41 fluorescence by His-37 protonation, and their antiviral potencies were evaluated against the replication of influenza virus A H2N2 and H3N2 subtypes and influenza virus B in MDCK cells. Of the various 2-alkyl-2-aminoadamantanes, and analogues, spiro[piperidine-2,2'-adamantane] 3 had the strongest M2 binding and antiviral potency, which were similar those of amantadine 1. The relative binding affinities suggested that the rigid carbon framework provided by the pyrrolidine or piperidine rings results in a more favorable orientation inside the M2 channel pore as compared to large, freely rotating alkyl groups. The aminoadamantane derivatives exhibited similar NMDA antagonistic activity to amantadine 1. A striking finding was the antiviral activity of the adamantanols 4, and 6, which lack any NMDA antagonist activity.
DOI: 10.1016/j.bmcl.2008.10.003
PubMed: 18947998
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000244
Links to Exploration step
pubmed:18947998Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.</title>
<author><name sortKey="Kolocouris, Antonios" sort="Kolocouris, Antonios" uniqKey="Kolocouris A" first="Antonios" last="Kolocouris">Antonios Kolocouris</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou, GR-15771 Athens, Greece. ankol@pharm.uoa.gr</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou, GR-15771 Athens</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Spearpoint, Philip" sort="Spearpoint, Philip" uniqKey="Spearpoint P" first="Philip" last="Spearpoint">Philip Spearpoint</name>
</author>
<author><name sortKey="Martin, Stephen R" sort="Martin, Stephen R" uniqKey="Martin S" first="Stephen R" last="Martin">Stephen R. Martin</name>
</author>
<author><name sortKey="Hay, Alan J" sort="Hay, Alan J" uniqKey="Hay A" first="Alan J" last="Hay">Alan J. Hay</name>
</author>
<author><name sortKey="L Pez Querol, Marta" sort="L Pez Querol, Marta" uniqKey="L Pez Querol M" first="Marta" last="L Pez-Querol">Marta L Pez-Querol</name>
</author>
<author><name sortKey="Sureda, Francesc X" sort="Sureda, Francesc X" uniqKey="Sureda F" first="Francesc X" last="Sureda">Francesc X. Sureda</name>
</author>
<author><name sortKey="Padalko, Elizaveta" sort="Padalko, Elizaveta" uniqKey="Padalko E" first="Elizaveta" last="Padalko">Elizaveta Padalko</name>
</author>
<author><name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18947998</idno>
<idno type="pmid">18947998</idno>
<idno type="doi">10.1016/j.bmcl.2008.10.003</idno>
<idno type="wicri:Area/PubMed/Corpus">000244</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000244</idno>
<idno type="wicri:Area/PubMed/Curation">000244</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000244</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.</title>
<author><name sortKey="Kolocouris, Antonios" sort="Kolocouris, Antonios" uniqKey="Kolocouris A" first="Antonios" last="Kolocouris">Antonios Kolocouris</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou, GR-15771 Athens, Greece. ankol@pharm.uoa.gr</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou, GR-15771 Athens</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Spearpoint, Philip" sort="Spearpoint, Philip" uniqKey="Spearpoint P" first="Philip" last="Spearpoint">Philip Spearpoint</name>
</author>
<author><name sortKey="Martin, Stephen R" sort="Martin, Stephen R" uniqKey="Martin S" first="Stephen R" last="Martin">Stephen R. Martin</name>
</author>
<author><name sortKey="Hay, Alan J" sort="Hay, Alan J" uniqKey="Hay A" first="Alan J" last="Hay">Alan J. Hay</name>
</author>
<author><name sortKey="L Pez Querol, Marta" sort="L Pez Querol, Marta" uniqKey="L Pez Querol M" first="Marta" last="L Pez-Querol">Marta L Pez-Querol</name>
</author>
<author><name sortKey="Sureda, Francesc X" sort="Sureda, Francesc X" uniqKey="Sureda F" first="Francesc X" last="Sureda">Francesc X. Sureda</name>
</author>
<author><name sortKey="Padalko, Elizaveta" sort="Padalko, Elizaveta" uniqKey="Padalko E" first="Elizaveta" last="Padalko">Elizaveta Padalko</name>
</author>
<author><name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</author>
</analytic>
<series><title level="j">Bioorganic & medicinal chemistry letters</title>
<idno type="eISSN">1464-3405</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adamantane (analogs & derivatives)</term>
<term>Adamantane (chemical synthesis)</term>
<term>Adamantane (chemistry)</term>
<term>Adamantane (pharmacology)</term>
<term>Amantadine (pharmacology)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Influenza A virus (drug effects)</term>
<term>Molecular Structure</term>
<term>N-Methylaspartate (antagonists & inhibitors)</term>
<term>Structure-Activity Relationship</term>
<term>Viral Matrix Proteins (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adamantane ()</term>
<term>Adamantane (analogues et dérivés)</term>
<term>Adamantane (pharmacologie)</term>
<term>Adamantane (synthèse chimique)</term>
<term>Amantadine (pharmacologie)</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>N-Méthyl-aspartate (antagonistes et inhibiteurs)</term>
<term>Protéines de la matrice virale ()</term>
<term>Relation structure-activité</term>
<term>Structure moléculaire</term>
<term>Virus de la grippe A ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adamantane</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adamantane</term>
<term>Amantadine</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>N-Méthyl-aspartate</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adamantane</term>
<term>Amantadine</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Molecular Structure</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adamantane</term>
<term>Antiviraux</term>
<term>Protéines de la matrice virale</term>
<term>Relation structure-activité</term>
<term>Structure moléculaire</term>
<term>Virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The new 2-alkyl-2-aminoadamantanes and analogues 4-10 were designed and synthesized by simplification of the structure of the potent anti-influenza virus A spiranic aminoadamantane heterocycles 2 and 3. The aim of the present work was to examine the effects of bulky and extended lipophilic moieties attached to amantadine 1 on binding to the M2 channel and the resulting antiviral potency. The binding affinities of the compounds to the M2 protein of influenza virus A/chicken/Germany/27 (Weybridge strain; H7N7) were measured for the first time using an assay based on quenching of Trp-41 fluorescence by His-37 protonation, and their antiviral potencies were evaluated against the replication of influenza virus A H2N2 and H3N2 subtypes and influenza virus B in MDCK cells. Of the various 2-alkyl-2-aminoadamantanes, and analogues, spiro[piperidine-2,2'-adamantane] 3 had the strongest M2 binding and antiviral potency, which were similar those of amantadine 1. The relative binding affinities suggested that the rigid carbon framework provided by the pyrrolidine or piperidine rings results in a more favorable orientation inside the M2 channel pore as compared to large, freely rotating alkyl groups. The aminoadamantane derivatives exhibited similar NMDA antagonistic activity to amantadine 1. A striking finding was the antiviral activity of the adamantanols 4, and 6, which lack any NMDA antagonist activity.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18947998</PMID>
<DateCompleted><Year>2009</Year>
<Month>01</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3405</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>23</Issue>
<PubDate><Year>2008</Year>
<Month>Dec</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Bioorganic & medicinal chemistry letters</Title>
<ISOAbbreviation>Bioorg. Med. Chem. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.</ArticleTitle>
<Pagination><MedlinePgn>6156-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2008.10.003</ELocationID>
<Abstract><AbstractText>The new 2-alkyl-2-aminoadamantanes and analogues 4-10 were designed and synthesized by simplification of the structure of the potent anti-influenza virus A spiranic aminoadamantane heterocycles 2 and 3. The aim of the present work was to examine the effects of bulky and extended lipophilic moieties attached to amantadine 1 on binding to the M2 channel and the resulting antiviral potency. The binding affinities of the compounds to the M2 protein of influenza virus A/chicken/Germany/27 (Weybridge strain; H7N7) were measured for the first time using an assay based on quenching of Trp-41 fluorescence by His-37 protonation, and their antiviral potencies were evaluated against the replication of influenza virus A H2N2 and H3N2 subtypes and influenza virus B in MDCK cells. Of the various 2-alkyl-2-aminoadamantanes, and analogues, spiro[piperidine-2,2'-adamantane] 3 had the strongest M2 binding and antiviral potency, which were similar those of amantadine 1. The relative binding affinities suggested that the rigid carbon framework provided by the pyrrolidine or piperidine rings results in a more favorable orientation inside the M2 channel pore as compared to large, freely rotating alkyl groups. The aminoadamantane derivatives exhibited similar NMDA antagonistic activity to amantadine 1. A striking finding was the antiviral activity of the adamantanols 4, and 6, which lack any NMDA antagonist activity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kolocouris</LastName>
<ForeName>Antonios</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou, GR-15771 Athens, Greece. ankol@pharm.uoa.gr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Spearpoint</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Martin</LastName>
<ForeName>Stephen R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hay</LastName>
<ForeName>Alan J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>López-Querol</LastName>
<ForeName>Marta</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sureda</LastName>
<ForeName>Francesc X</ForeName>
<Initials>FX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Padalko</LastName>
<ForeName>Elizaveta</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Neyts</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Clercq</LastName>
<ForeName>Erik</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>MC_U117512708</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>10</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Bioorg Med Chem Lett</MedlineTA>
<NlmUniqueID>9107377</NlmUniqueID>
<ISSNLinking>0960-894X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C488937">M2 protein, Influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6384-92-5</RegistryNumber>
<NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber>
<NameOfSubstance UI="D000547">Amantadine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>PJY633525U</RegistryNumber>
<NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000218" MajorTopicYN="Y">Adamantane</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>08</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>09</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>10</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>1</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18947998</ArticleId>
<ArticleId IdType="pii">S0960-894X(08)01199-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.bmcl.2008.10.003</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000244 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000244 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:18947998 |texte= Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18947998" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |